SNPs showing significant association with CLL outcome
| . | Reference allele . | Genotype at risk . | N* . | HR . | 95% CI . | P§ . | q∥ . |
|---|---|---|---|---|---|---|---|
| TTFT | |||||||
| BARD1 rs2229571 | C | CG/GG | 198 | 0.69† | 0.49-0.95 | .026 | 0.486 |
| LILRA4 rs2241384 | C | TT | 7 | 2.69† | 1.07-6.74 | .034 | 0.490 |
| ERBB2IP rs3213837 | G | GA/AA | 70 | 1.53† | 1.06-2.21 | .020 | 0.486 |
| LRP2 rs4667591 | G | GT/TT | 106 | 1.43† | 1.04-1.96 | .027 | 0.486 |
| THBS1 rs2228262 | A | AG/GG | 74 | 0.59† | 0.40-0.86 | .007 | 0.486 |
| OS from diagnosis | |||||||
| BARD1 rs2229571 | C | CG/GG | 198 | 0.57† | 0.36-0.90 | .017 | 0.586 |
| BARD1 rs2229571 | C | GG | 69 | 0.54† | 0.30-0.98 | .043 | 0.586 |
| FHL5 rs9373985 | C | CG/GG | 202 | 0.62† | 0.40-0.98 | .042 | 0.586 |
| MGMT rs12917 | C | TT | 7 | 7.28† | 2.42-21.88 | < .001 | 0.022¶ |
| PFS from first treatment | |||||||
| APOE rs7412 | C | CT/TT | 16 | 2.15‡ | 1.19-3.89 | .011 | 0.648 |
| BARD1 rs2229571 | C | CG/GG | 91 | 0.64‡ | 0.43-0.95 | .029 | 0.648 |
| OS from first treatment | |||||||
| APOE rs7412 | C | CT/TT | 16 | 3.20‡ | 1.47-6.94 | .003 | 0.183¶ |
| BARD1 rs2229571 | C | CG/GG | 91 | 0.47‡ | 0.26-0.84 | .012 | 0.366 |
| BARD1 rs2229571 | C | GG | 31 | 0.48‡ | 0.24-0.97 | .042 | 0.453 |
| KLRC4 rs1841958 | C | CA/AA | 96 | 0.57‡ | 0.33-0.99 | .047 | 0.453 |
| THBS1 rs2228262 | A | AG/GG | 35 | 1.85‡ | 1.00-3.40 | .047 | 0.453 |
| XRCC2 rs3218536 | G | GA/AA | 29 | 0.43‡ | 0.19-0.95 | .037 | 0.453 |
| . | Reference allele . | Genotype at risk . | N* . | HR . | 95% CI . | P§ . | q∥ . |
|---|---|---|---|---|---|---|---|
| TTFT | |||||||
| BARD1 rs2229571 | C | CG/GG | 198 | 0.69† | 0.49-0.95 | .026 | 0.486 |
| LILRA4 rs2241384 | C | TT | 7 | 2.69† | 1.07-6.74 | .034 | 0.490 |
| ERBB2IP rs3213837 | G | GA/AA | 70 | 1.53† | 1.06-2.21 | .020 | 0.486 |
| LRP2 rs4667591 | G | GT/TT | 106 | 1.43† | 1.04-1.96 | .027 | 0.486 |
| THBS1 rs2228262 | A | AG/GG | 74 | 0.59† | 0.40-0.86 | .007 | 0.486 |
| OS from diagnosis | |||||||
| BARD1 rs2229571 | C | CG/GG | 198 | 0.57† | 0.36-0.90 | .017 | 0.586 |
| BARD1 rs2229571 | C | GG | 69 | 0.54† | 0.30-0.98 | .043 | 0.586 |
| FHL5 rs9373985 | C | CG/GG | 202 | 0.62† | 0.40-0.98 | .042 | 0.586 |
| MGMT rs12917 | C | TT | 7 | 7.28† | 2.42-21.88 | < .001 | 0.022¶ |
| PFS from first treatment | |||||||
| APOE rs7412 | C | CT/TT | 16 | 2.15‡ | 1.19-3.89 | .011 | 0.648 |
| BARD1 rs2229571 | C | CG/GG | 91 | 0.64‡ | 0.43-0.95 | .029 | 0.648 |
| OS from first treatment | |||||||
| APOE rs7412 | C | CT/TT | 16 | 3.20‡ | 1.47-6.94 | .003 | 0.183¶ |
| BARD1 rs2229571 | C | CG/GG | 91 | 0.47‡ | 0.26-0.84 | .012 | 0.366 |
| BARD1 rs2229571 | C | GG | 31 | 0.48‡ | 0.24-0.97 | .042 | 0.453 |
| KLRC4 rs1841958 | C | CA/AA | 96 | 0.57‡ | 0.33-0.99 | .047 | 0.453 |
| THBS1 rs2228262 | A | AG/GG | 35 | 1.85‡ | 1.00-3.40 | .047 | 0.453 |
| XRCC2 rs3218536 | G | GA/AA | 29 | 0.43‡ | 0.19-0.95 | .037 | 0.453 |
CI indicates confidence interval, and HR, hazard ratio.
Number of patients with at-risk genotype.
HR adjusted for (?) age, sex, Binet stage, immunoglobulin gene mutations, CD38 expression, TP53 deletion/mutation at diagnosis for TTFT and OS from diagnosis.
age, sex, Binet stage, immunoglobulin gene mutations, CD38 expression, TP53 deletion/mutation, and treatment regimen for PFS and OS from first treatment.
P value (calculated by Cox regression) considered significant if < .05.
q value calculated by false discovery rate to adjust for multiple testing.
Significant (q < 0.2).